Literature DB >> 10864929

Inhibition of the initiation of HIV-1 reverse transcription by 3'-azido-3'-deoxythymidine. Comparison with elongation.

M Rigourd1, J M Lanchy, S F Le Grice, B Ehresmann, C Ehresmann, R Marquet.   

Abstract

Initiation of human immunodeficiency virus-1 reverse transcription requires formation of a complex containing the viral RNA, primer tRNA(3)(Lys), and reverse transcriptase. Initiation, corresponding to addition of the first six nucleotides to tRNA(3)(Lys), is distinguished from elongation by its high specificity and low efficiency (processivity). Here, we compared the inhibition of initiation and elongation of reverse transcription by 3'-azido-3'-deoxythymidine 5'-triphosphate (AZTTP), the active form of 3'-azido-3'-deoxythymidine. We report the first detailed study of nucleotide binding, discrimination, and pyrophosphorolysis by the authentic initiation complex. We showed that the initiation and elongation complexes bound AZTTP and dTTP with the same affinity, while the polymerization rates were reduced by 148-160-fold during initiation. The pyrophosphorolysis rate of dTTP was reduced by the same extent, indicating that the polymerization equilibrium is the same in the two phases. The efficient unblocking of the 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated primer by pyrophosphorolysis significantly relieved inhibition of DNA synthesis during elongation in the presence of physiological pyrophosphate concentrations. Remarkably, although pyrophosphorolysis of dTMP and AZTMP were equally efficient during elongation, reverse transcriptase was almost totally unable to unblock the AZTMP-terminated primer during initiation. As a result, inhibition of reverse transcription by AZTTP was more efficient during initiation than elongation of reverse transcription, despite a reduced selectivity of incorporation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864929     DOI: 10.1074/jbc.M003262200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Assembly, purification and crystallization of an active HIV-1 reverse transcriptase initiation complex.

Authors:  Janice D Pata; Bradford R King; Thomas A Steitz
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

Review 3.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

4.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

5.  Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.

Authors:  Janice D Pata; William G Stirtan; Steven W Goldstein; Thomas A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Initiation complex dynamics direct the transitions between distinct phases of early HIV reverse transcription.

Authors:  Shixin Liu; Bryan T Harada; Jennifer T Miller; Stuart F J Le Grice; Xiaowei Zhuang
Journal:  Nat Struct Mol Biol       Date:  2010-11-21       Impact factor: 15.369

7.  Initiation of HIV Reverse Transcription.

Authors:  Catherine Isel; Chantal Ehresmann; Roland Marquet
Journal:  Viruses       Date:  2010-01-18       Impact factor: 5.818

8.  Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptase.

Authors:  Scott J Garforth; Michael A Parniak; Vinayaka R Prasad
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

9.  Peptides derived from HIV-1 integrase that bind Rev stimulate viral genome integration.

Authors:  Aviad Levin; Zvi Hayouka; Markus Helfer; Ruth Brack-Werner; Assaf Friedler; Abraham Loyter
Journal:  PLoS One       Date:  2009-01-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.